A carregar...
Neratinib augments the lethality of [regorafenib + sildenafil]
Regorafenib is approved for the treatment of colorectal cancer and hepatocellular carcinoma. In the trial NCT02466802 we have discovered that regorafenib can be safely combined with the PDE5 inhibitor sildenafil in advanced solid tumor patients. The present studies determined whether the approved ER...
Na minha lista:
| Publicado no: | J Cell Physiol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6322207/ https://ncbi.nlm.nih.gov/pubmed/30203445 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcp.27276 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|